SCHEMBL3998063

SCHEMBL3998063

O=C1[N]C2(CCN(C(=O)COCc3ccccc3)CC2)NC1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 12/20 0.49
ALDH1A1 P00352 1/20 0.44
RAB9A P51151 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4001759 0.83 KMT2A (0.42) ALDH1A1CYP2D6
SCHEMBL4002141 0.81 KMT2A (0.40) ALDH1A1RAB9A
SCHEMBL5668375 0.81 MEN1 (0.45) ALDH1A1
SCHEMBL1803072 0.80 GRM5 (0.48) GRM5ALDH1A1CYP2D6
SCHEMBL5666899 0.80 SMN1; SMN2 (0.51) ALDH1A1RAB9A
SCHEMBL5667080 0.80 LMNA (0.49) ALDH1A1
SCHEMBL2940845 0.79 GRM5 (0.47) GRM5ALDH1A1RAB9A
SCHEMBL5668605 0.79 MEN1 (0.46) ALDH1A1
SCHEMBL3999620 0.78 MAPK1 (0.46) ALDH1A1
SCHEMBL4003459 0.77 CYP2C9 (0.56) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005095402-A9 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2009-06-11 WO claimed
EP-1730147-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2006-12-13 EP claimed
WO-2005095402-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2005-10-13 WO claimed
WO-2005095402-A9 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2009-06-11 WO disclosed